Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Market Cap: US$167.6m

Tenaya Therapeutics Future Growth

Future criteria checks 5/6

Tenaya Therapeutics is forecast to grow earnings and revenue by 60.9% and 59.7% per annum respectively. EPS is expected to grow by 58.5% per annum. Return on equity is forecast to be -71.1% in 3 years.

Key information

60.9%

Earnings growth rate

58.46%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate59.7%
Future return on equity-71.07%
Analyst coverage

Good

Last updated18 May 2026

Recent future growth updates

Recent updates

Analysis Article • May 05

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 05

Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform

Summary Tenaya Therapeutics develops gene therapies and small molecules for inherited cardiomyopathies. They have TN-201 for HCM, TN-401 for ARVC, and HDAC6 inhibitor TN-301. Management positions its AAV9 platform and internal manufacturing as a reusable engine for multiple cardiac genetic medicines. Thus, TNYA can potentially target several other mutation-defined patient populations at some point. However, TNYA remains pre-revenues, and it’s a thinly traded microcap. Its tight cash runway is also a concern. Lastly, the FDA put a clinical hold on TN-201. So, all of these risks ultimately nudge me towards a neutral “Hold” on TNYA for now. Read the full article on Seeking Alpha
Analysis Article • Sep 21

Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 20

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 23

Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 30

Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease

Summary Tenaya Therapeutics, Inc.'s TN-201 gene therapy showed promising early results in MYBPC3-HCM patients, with increased RNA expression and protein levels, but the stock remains a “Hold.”. Key data updates from the phase 1b/2 MyPEAK-1 study, including higher dosing results, are expected in 2025, potentially impacting stock performance. TNYA is also advancing TN-401 for PKP2-ARVC, with phase 1b RIDGE-1 study results anticipated in 2025, diversifying its pipeline. Financially, Tenaya had $79.5M in cash as of September 30th 2024 but may need to raise funds in early 2025, possibly leveraging the $45M credit facility it could tap into. Read the full article on Seeking Alpha
Analysis Article • Sep 18

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 04

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 20

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 08

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Mar 07

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 06

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Tenaya Therapeutics (NASDAQ:TNYA) said the U.S. Food and Drug Administration had cleared its application to begin clinical testing of TN-301 to potentially treat heart failure with preserved ejection fraction (HFpEF). (TNYA) rose 3.1% before the bell. Tenaya has begun its first-in-human Phase 1 clinical trial of TN-301 in healthy adult participants. HFpEF is a complex disease that involves systemic inflammation, left ventricular hypertrophy, fibrosis, and diastolic dysfunction factors, and is estimated to affect more than three million people in the U.S. alone. In Stage 1, participants will receive single ascending doses (SAD) of either TN-301 or placebo.
Seeking Alpha • Aug 10

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Tenaya Therapeutics press release (NASDAQ:TNYA): Q2 GAAP EPS of -$0.69 beats by $0.07.  cash, cash equivalents and investments in marketable securities were $180.9 million
Analysis Article • Aug 08

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 03

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Nov 01

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 06

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Tenaya Therapeutics is developing therapies for rare genetic disorders and more prevalent cardiovascular diseases. The Company has three distinct but interrelated product platforms. Tenaya just closed an upsized IPO with gross proceeds of about $207 million.

Earnings and Revenue Growth Forecasts

NasdaqGS:TNYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028278121N/AN/A4
12/31/2027N/A-109N/AN/A4
12/31/20269-86N/AN/A6
3/31/20260-83-65-64N/A
12/31/2025N/A-91-69-68N/A
9/30/2025N/A-94-73-73N/A
6/30/2025N/A-100-78-77N/A
3/31/2025N/A-106-86-85N/A
12/31/2024N/A-111-92-91N/A
9/30/2024N/A-117-95-94N/A
6/30/2024N/A-121-99-98N/A
3/31/2024N/A-125-102-100N/A
12/31/2023N/A-124-103-102N/A
9/30/2023N/A-128-104-103N/A
6/30/2023N/A-129-112-107N/A
3/31/2023N/A-124-119-106N/A
12/31/2022N/A-124-125-104N/A
9/30/2022N/A-116-130-98N/A
6/30/2022N/A-104-121-87N/A
3/31/2022N/A-91-103-74N/A
12/31/2021N/A-73-86-61N/A
9/30/2021N/A-57-76-55N/A
6/30/2021N/A-49-64-48N/A
3/31/2021N/A-42-57-43N/A
12/31/2020N/A-38-45-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNYA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: TNYA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TNYA is expected to become profitable in the next 3 years.

Revenue vs Market: TNYA's revenue (59.7% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: TNYA's revenue (59.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TNYA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 10:36
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tenaya Therapeutics, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Yevgeniya LivshitsChardan Capital Markets, LLC
Emanuela BranchettiH.C. Wainwright & Co.